[go: up one dir, main page]

WO1995006727A3 - Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease - Google Patents

Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease Download PDF

Info

Publication number
WO1995006727A3
WO1995006727A3 PCT/US1994/010257 US9410257W WO9506727A3 WO 1995006727 A3 WO1995006727 A3 WO 1995006727A3 US 9410257 W US9410257 W US 9410257W WO 9506727 A3 WO9506727 A3 WO 9506727A3
Authority
WO
WIPO (PCT)
Prior art keywords
mog
autoimmune disease
autoimmune diseases
myelin oligodendrocyte
oligodendrocyte glycoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1994/010257
Other languages
French (fr)
Other versions
WO1995006727A2 (en
Inventor
Brigitte Devaux
Jonathan B Rothbard
Dawn Smilek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immulogic Pharmaceutical Corp
Original Assignee
Immulogic Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharmaceutical Corp filed Critical Immulogic Pharmaceutical Corp
Priority to EP94928084A priority Critical patent/EP0716696A1/en
Priority to JP7508328A priority patent/JPH09502346A/en
Priority to NZ273813A priority patent/NZ273813A/en
Priority to FI961000A priority patent/FI961000L/en
Priority to AU77258/94A priority patent/AU7725894A/en
Priority to KR1019960701093A priority patent/KR960705038A/en
Publication of WO1995006727A2 publication Critical patent/WO1995006727A2/en
Publication of WO1995006727A3 publication Critical patent/WO1995006727A3/en
Priority to NO960858A priority patent/NO960858D0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Rehabilitation Therapy (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

The present invention provides a nucleic acid molecule having a nucleotide sequence encoding human MOG, an autoantigen related to demyelinating autoimmune diseases. The present invention also provides recombinantly produced human MOG or antigenic fragments. Antigenic fragments of MOG, which can be prepared synthetically, represent T-cell epitopes of human MOG. Human MOG and fragments thereof are useful for diagnosing and treating autoimmune diseases. Further, methods of screening for, and developing therapeutics useful in the treatment of autoimmune diseases are also disclosed.
PCT/US1994/010257 1993-09-03 1994-09-01 Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease Ceased WO1995006727A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP94928084A EP0716696A1 (en) 1993-09-03 1994-09-01 Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
JP7508328A JPH09502346A (en) 1993-09-03 1994-09-01 Use of myelin oligodendrocyte glycoprotein and its peptide moieties in protocols associated with autoimmune disease
NZ273813A NZ273813A (en) 1993-09-03 1994-09-01 Myelin oligodendrocyte glycoprotein autoantigen
FI961000A FI961000L (en) 1993-09-03 1994-09-01 Uses of myelin oligodendrocyte glycoprotein and peptide fragments thereof in methods related to autoimmune diseases
AU77258/94A AU7725894A (en) 1993-09-03 1994-09-01 Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
KR1019960701093A KR960705038A (en) 1993-09-03 1994-09-01 USES OF MYELIN OLIGODENDROCYTE GLYCOPROTEIN AND PEPTIDE PORTIONS THEREOF IN PROTOCOLS RELATED TO AUTOIMMUNE DESEASE
NO960858A NO960858D0 (en) 1993-09-03 1996-03-01 Uses of myelin - oligodendrocyte glycoprotein and peptide portions thereof in autoimmune disease methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11682493A 1993-09-03 1993-09-03
US08/116,824 1993-09-03

Publications (2)

Publication Number Publication Date
WO1995006727A2 WO1995006727A2 (en) 1995-03-09
WO1995006727A3 true WO1995006727A3 (en) 1995-04-13

Family

ID=22369451

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/010257 Ceased WO1995006727A2 (en) 1993-09-03 1994-09-01 Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease

Country Status (9)

Country Link
EP (1) EP0716696A1 (en)
JP (1) JPH09502346A (en)
KR (1) KR960705038A (en)
AU (1) AU7725894A (en)
CA (1) CA2170901A1 (en)
FI (1) FI961000L (en)
NO (1) NO960858D0 (en)
NZ (1) NZ273813A (en)
WO (1) WO1995006727A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2203629A1 (en) * 1994-10-25 1996-05-02 Dawn Smilek Compositions and treatment for multiple sclerosis
EP0830139B1 (en) * 1995-05-02 2008-01-02 Alexion Pharmaceuticals, Inc. Modified myelin protein molecules
WO1997035879A1 (en) * 1996-03-28 1997-10-02 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof
WO1998033912A1 (en) * 1997-01-30 1998-08-06 Human Genome Sciences, Inc. MYELIN OLIGODENDROCYTE GLYCOPROTEIN-LIKE PROTEIN (MOGp) AND METHODS OF USE
SE9703287D0 (en) * 1997-09-11 1997-09-11 Astra Ab Peptides
ZA9810133B (en) * 1997-11-07 1999-05-17 Biogen Inc BMOG a novel protein member of the myelin-oligodendrocyte glycoprotein family and its use for ummonomodulatory purposes
CA2341240C (en) * 1998-08-26 2008-04-01 The Regents Of The University Of California Autoantibody inhibitors
CN1301756A (en) * 1999-12-29 2001-07-04 复旦大学 New polypeptide-myelin PO protein 14 and polynucleotide coding such polypeptide
CN1352087A (en) * 2000-11-02 2002-06-05 上海博德基因开发有限公司 New polypeptide-human glycoprotein 42 and polynucleotide for encoding such polypeptide
WO2007008933A2 (en) * 2005-07-11 2007-01-18 Carantech Biosciences, Inc. Compositions and methods comprising complex alternative splice variants of myelin/oligodendrocyte genes (mogs) and antibodies directed thereto
CN101897964B (en) * 2009-04-27 2013-04-10 中国农业大学 Medicament for preventing autoimmune disease
WO2013020914A1 (en) * 2011-08-10 2013-02-14 Celares Gmbh Peg-conjugated peptides
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
AU2015249328B2 (en) * 2014-04-24 2019-01-17 University Of Florida Research Foundation, Inc. AAV-based gene therapy for multiple sclerosis
EP3560955A4 (en) * 2016-12-26 2020-12-23 Kyowa Kirin Co., Ltd. ANTIBODY CAPABLE OF BINDING TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN
WO2021211614A1 (en) 2020-04-14 2021-10-21 University Of Florida Research Foundation, Incorporated Aav-based gene therapies for treatment of autoimmune diseases
US11334352B1 (en) 2020-12-29 2022-05-17 Kpn Innovations, Llc. Systems and methods for generating an immune protocol for identifying and reversing immune disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DANIEL D. MIKOL ET AL.: "The oligodendrocyte-myelin glycoprotein belongs to a distinct family of proteins and contains the HNK-1 carbohydrate", THE JOURNAL OF CELL BIOLOGY, vol. 110, no. 2, February 1990 (1990-02-01), pages 471 - 479 *
N. KERLERO DE ROSBO ET AL.: "Reactivity to myelin antigens in multiple sclerosis", JOURNAL OF CLINICAL INVESTIGATION, vol. 92, no. 6, December 1993 (1993-12-01), pages 2602 - 2608 *
S. ABO ET AL.: "Preparation of highly purified human myelin oligodendrocyte glycoprotein in quantities sufficient for encephalitogenicity and immunogenicity studies", BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL, vol. 30, no. 5, August 1993 (1993-08-01), pages 945 - 958 *

Also Published As

Publication number Publication date
FI961000A0 (en) 1996-03-04
NZ273813A (en) 1998-05-27
AU7725894A (en) 1995-03-22
JPH09502346A (en) 1997-03-11
KR960705038A (en) 1996-10-09
WO1995006727A2 (en) 1995-03-09
NO960858L (en) 1996-03-01
FI961000A7 (en) 1996-03-04
NO960858D0 (en) 1996-03-01
CA2170901A1 (en) 1995-03-09
FI961000L (en) 1996-03-04
EP0716696A1 (en) 1996-06-19

Similar Documents

Publication Publication Date Title
WO1995006727A3 (en) Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
EP2311952A3 (en) Antibodies to MRT-1 protein or fragments thereof
WO2001039796A3 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
EP2258383A3 (en) Antigenic peptides derived from telomerase
TW264480B (en)
WO2002096937A3 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO1995029193A3 (en) Melanoma antigens
WO2002006339A3 (en) Proteins and nucleic acids encoding same
KR960703014A (en) ISOLATED PEPTIDES WHICH FORM COMPLEXES WITH MHC MOLECULE HLA-C-CLONE 10 AND USES THEREOF
CA2082382A1 (en) Variant cd44 surface proteins, dna sequences coding them, antibodies against these proteins and their use in diagnosis and therapy
WO1994021675A3 (en) T cell epitopes of ryegrass pollen allergen
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
WO2002057453A3 (en) Polypetides and nucleic acids encoding same
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
EP1114861A4 (en) Ly6h gene
WO2001029217A3 (en) Novel polypeptides and polynucleotides encoding same
WO2001081578A3 (en) Novel proteins and nucleic acids encoding same
WO1993021321A3 (en) T CELL EPITOPES OF THE MAJOR ALLERGENS FROM $i(AMBROSIA ARTEMISIIFOLIA)
WO1996018646A3 (en) Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
EP0773290A3 (en) Novel LDL receptor analog protein and the gene coding therefor
WO2002059146A3 (en) Peptides having affinity for the gp120 viral protein and use thereof
GEP20043386B (en) β -Amyloid Peptide-Binding Proteins and Polynucleotides Encoding the Same
BR9911601A (en) Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
WO2001040291A3 (en) Proteins and nucleic acids encoding the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 273813

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2170901

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 961000

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1994928084

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994928084

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1994928084

Country of ref document: EP